文献速递血栓与止血白血病

疑似家族性血小板病RUNX1胚系变异的功能分析

Functional analysis of germline RUNX1 variants identified in individuals with suspected familial platelet disorder.
PubMed 文献 · Blood Adv · 2026-01-01

该研究针对在NIH RUNX1自然史研究中发现的26个RUNX1意义不明变异(VUS),建立了一套体外功能检测流程,包括反式激活报告基因、电泳迁移率变动、Western blot和免疫荧光。整合功能数据、人群等位基因频率、计算机预测及临床表型与共分离数据后,17个变异得以重新分类,并揭示了当前MM-VCEP指南阈值过严及现有检测对C端变异敏感性不足的局限。

要点

  • 综合功能检测可助力RUNX1 VUS重新分类,本研究重新分类了17个变异。
  • 现行MM-VCEP指南阈值过严,可能漏判功能受损变异。
  • 现有检测对RUNX1 C端变异的致病性捕捉不足。

核心结论

  • 综合体外功能数据可支持RUNX1变异分类并辅助临床解读。
  • 当前MM-VCEP指南阈值过严,可能排除功能受损变异。
  • 现有检测对RUNX1 C端变异的致病性捕捉不足。

研究设计与样本

  • 研究纳入NIH RUNX1自然史研究中发现的26个RUNX1 VUS,并设5个良性及6个致病性变异对照。
  • 采用反式激活报告基因、电泳迁移率变动、Western blot与细胞分级分离及免疫荧光定位等功能检测。

主要发现

  • 功能数据整合人群等位基因频率、计算机预测及临床表型与共分离数据后,17个变异被重新分类。
  • 研究发现当前MM-VCEP指南阈值过严,将功能受损变异排除在分类之外。
  • 研究显示现有获批检测不能充分捕捉RUNX1 C端变异的致病影响。

临床怎么用

  • 对疑似FPDMM个体的RUNX1 VUS,可结合综合功能检测数据辅助分类与临床解读。
  • 解读RUNX1变异时需注意现有指南阈值和检测方法对C端变异的局限。

局限性

  • 研究强调需开发更多功能检测,尤其针对RUNX1 C端变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Deleterious germline RUNX1 variants lead to familial platelet disorder with myeloid malignancies (FPDMM), an autosomal dominant disorder characterized by thrombocytopenia, qualitative platelet defects, and an increased risk of hematologic malignancies. Interpretation of variants of uncertain significance (VUSs) remains a major barrier to precision medicine for affected individuals and families, particularly because many RUNX1 variants are private. To address this challenge, we developed a comprehensive pipeline of well-established in vitro functional assays, including transactivation reporter assays, electrophoretic mobility shift assays, western blot with cell fractionation, and immunofluorescence imaging to assess subcellular localization. We evaluated the functional impact of 26 RUNX1 VUSs identified in individuals referred to the National Institutes of Health RUNX1 Natural History Study. Among these, 5 established benign and 6 pathogenic variants were included as controls. Functional data were integrated with population allele frequencies, in silico predictions, and clinical phenotype and segregation data, enabling reclassification of 17 variants. Our findings also reveal key limitations of the current Myeloid Malignancy Variant Curation Expert Panel guidelines for variant interpretation, including overly stringent thresholds that exclude functionally impaired variants from classification. In addition, we demonstrate that currently approved assays inadequately capture the pathogenic impact of C-terminal variants. These results underscore the importance of comprehensive functional data to support RUNX1 variant classification and inform clinical interpretation. Moreover, this work facilitates investigation of FPDMM pathogenesis and supports refinement of RUNX1-specific variant curation guidelines. We further advocate for development of additional functional assays, especially for variants affecting the RUNX1 C-terminus.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Menezes AC, Deuitch NT, Pintuff A, et al. Functional analysis of germline RUNX1 variants identified in individuals with suspected familial platelet disorder. Blood Adv. 2026. PMID: 42308221. doi:10.1182/bloodadvances.2026019984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。